Business Wire

TEMENOS

Share
Temenos Ramps up AI Efforts to Power its Digital Banking Platform

Temenos (SIX: TEMN), the banking software company, today announced during the Machine Learning Panel at Sibos that it is increasing the development of Artificial Intelligence capabilities throughout its digital banking platform. The Temenos AI initiative will enable banks to offer personalized services to customers, augment users’ decisions with data-driven machine intelligence, and maximise straight-through-processing (STP) rates for financial transactions at reduced cost with limited or no human intervention.

As part of this global initiative, Temenos has just launched a Centre of Excellence for Artificial Intelligence as its innovation engine. The Temenos AI Centre of Excellence will foster a collaborative ecosystem with Temenos’ banking clients and partners to help identify and validate use cases where AI could have an immediate impact on customer experience, as well as operational excellence, and hence improve the bottom line.

Temenos’ pioneering initiative will involve injecting AI throughout its packaged, digital banking platform available on premise and in the cloud. Temenos is assisting banks to get ‘AI-ready’ by providing modern data architectures and integration tools that promote real-time data quality and governance, and allow high volumes of data to be consumed by AI and machine learning-based applications. Temenos has invested heavily in AI across its technology stack from AI-based fraud detection tools, to machine-learning and predictive analytics models. Temenos also launched the ‘Robo-Advisor’, as part of its WealthSuite, a packaged solution that helps financial institutions improve returns and enhance their customer experience through a fully automated or a hybrid digital advisory service.

Prema Varadhan, Vice President of AI Centre of Excellence, Temenos, said : “Our drive for innovation is constant. We invest over 20% of our annual revenues in R&D, an amount that surpasses what a global Tier 1 bank would typically spend on its core banking systems, the bulk of which is usually spent on maintenance of legacy systems rather than innovation. Our vision is to build and fully embed own and third party AI capability throughout our banking platform to improve efficiency, automate processes, and crucially provide personalized customer engagements. AI is an integral part of our platform and an essential component in creating the intelligent bank of the future. We want to make AI capability accessible to all banks regardless of their type and size. Together with our customers and partners we aim to leverage our Centre of Excellence as an innovation engine that will enable banks harness the full potential of new technologies.”

Temenos AI Centre of Excellence will initially focus on the following:

  • Front office . Temenos will help banks embed AI to deliver compelling customer experiences, greater personalization and smoother on-boarding. This delivers cost savings and new revenue streams to banks. For example, Temenos Front Office Suite has numerous, integration, machine learning models, which mine transactional data to understand customer behaviors and patterns. The results of these models are integrated within the platform in order to provide customers with real-time product, service, or educational offers that enhance their financial lives.
  • Payments Exemption Handling. Temenos will use AI technologies to identify any payments going into exception, monitor users’ manual corrections, and learn how to fix and automate these payments, thereby improving STP rates and lowering costs.
  • Real-time fraud detection. Temenos is using AI to profile individual behaviours and detect fraud in real time. Banks need self-learning capabilities, beyond rules-based engines, to profile customer behaviour, using vast amounts of customer data and transactions to flag activities outside behavioural patterns that could be a potential fraud. Temenos is working towards using cloud computing to deliver new algorithms that help solve the real-time fraud detection challenge.

In a recent report*, Jost Hoppermann, Vice President and Principal Analyst, Forrester , wrote: “The artificial intelligence (AI) space has quickly become a key tool for leading banks to improve customer experience (CX), increase process efficiency, and drive revenue. AI's increasing maturity means that banks' application development and delivery (AD&D) teams should consider off-the-shelf banking software powered by AI. When the dust settles, AI will be embedded as part of all products." He went on to note that, "until recently, only larger banks were in a good position to gain these benefits because using AI required massive in-house skills or intensive help from a systems integrator. This is changing ... AI will move from being something special to a core technology — and banks of all shapes and sizes will have AI-powered banking applications.”

Temenos has been in the forefront of innovation and was the first to offer a core banking system with real-time 24/7 processing, the first to launch a core banking offering in the cloud in 2011, as well as the first to go to market in the cloud with a combined payments hub and core banking platform. Temenos was also first with its MarketPlace, an online digital store, which brings together over 150 financial software products from over 65 certified fintech partners that are fully pre-integrated into the Temenos software. Almost half of Temenos’ 5,000 employees are working in R&D.

*Leverage AI-Powered Banking Platforms To Support True Digital Banking, December 2017, Forrester

– Ends –

About Temenos

Temenos AG (SIX: TEMN), headquartered in Geneva, is the world’s leader in banking software, partnering with banks and other financial institutions to transform their businesses and stay ahead of a changing marketplace. Over 3,000 firms across the globe, including 41 of the top 50 banks, rely on Temenos to process the daily transactions of more than 500 million banking customers. Temenos customers are proven to be more profitable than their peers: over a seven-year period, they enjoyed on average a 31% higher return on assets, a 36% higher return on equity and an 8.6 percentage point lower cost/income ratio than banks running legacy applications. For more information please visit www.temenos.com .

Contact:

Temenos Global Public Relations Manager Jessica Wolfe Tel: +1 610 232 2793 Email : jessica.wolfe@temenos.com or Newgate Communications on behalf of Temenos Alistair Kellie & Andrew Adie Tel: +44 20 7680 6550 Email: allnewgatetemenos@newgatecomms.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye